Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT
Background: Hepatitis C virus (HCV) infection is frequently associated with B-cell non-Hodgkin's lymphomas. We investigated the prevalence of HCV infection in nongastric marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT) in order to define the relationship between the viral inf...
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2007-02, Vol.18 (2), p.346-350 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 350 |
|---|---|
| container_issue | 2 |
| container_start_page | 346 |
| container_title | Annals of oncology |
| container_volume | 18 |
| creator | Arcaini, L. Burcheri, S. Rossi, A. Paulli, M. Bruno, R. Passamonti, F. Brusamolino, E. Molteni, A. Pulsoni, A. Cox, M.C. Orsucci, L. Fabbri, A. Frezzato, M. Voso, M.T. Zaja, F. Montanari, F. Merli, M. Pascutto, C. Morra, E. Cortelazzo, S. Lazzarino, M. |
| description | Background: Hepatitis C virus (HCV) infection is frequently associated with B-cell non-Hodgkin's lymphomas. We investigated the prevalence of HCV infection in nongastric marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT) in order to define the relationship between the viral infection and the presenting features, treatment, and outcome.
Methods: We retrospectively studied 172 patients with a histological diagnosis of marginal zone B-cell lymphoma of MALT, except for stomach, and with available HCV serology, among a series of 208 patients.
Results: HCV infection was documented in 60 patients (35%). Most HCV-positive patients (97%) showed a single MALT organ involvement. HCV-positive patients showed a more frequent involvement of skin (35%), salivary glands (25%), and orbit (15%). The majority of stage IV HCV-positive patients (71%) had a single MALT site with bone marrow involvement. The overall response rate was similar in HCV-positive (93%) and HCV-negative patients (87%). Overall survival (OS) and event-free survival (EFS) did not differ according to HCV infection. In multivariate analysis, advanced disease (stage III–IV) was associated with a poorer OS (P = 0.0001), irrespective of HCV serostatus.
Conclusions: This study shows that nongastric marginal zone lymphomas are characterized by a high prevalence of HCV infection. Patients with involvement of a single MALT site have the highest prevalence of HCV. HCV-positive nongastric lymphomas of MALT show an indolent course similar to HCV-negative patients and seem an ideal target for exploiting the antilymphoma activity of antiviral treatments. |
| doi_str_mv | 10.1093/annonc/mdl388 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68985099</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753419376094</els_id><sourcerecordid>1212972471</sourcerecordid><originalsourceid>FETCH-LOGICAL-c570t-892d761b71e5528a03765b319a5f8b0ef898744254563e776db8cd72258dea293</originalsourceid><addsrcrecordid>eNqFkU1v1DAQhi0EokvhyBVFSHALteP461hWhUUsKqACFRfLcSbFJbG3drai_fU4zYqVkBAnj-RnXs_4Qegpwa8IVvTIeB-8PRrankp5Dy0I46qUuCb30QKripaC0foAPUrpEmPMVaUeogMisCCKigU6_Rjh2vTgLRShK1bLr4XzHdjRBZ-rIodfmDRGZ4vBxAvnTV_cBg_F69JC3xf9zbD5EQYzNX84Xp89Rg860yd4sjsP0Zc3J2fLVbk-fftuebwuLRN4LKWqWsFJIwgwVkmDqeCsoUQZ1skGQyeVFHVdsZpxCkLwtpG2FVXFZAumUvQQvZxzNzFcbSGNenBpmsh4CNukeQ5gWP0fJIoJyu8Sn_8FXoZtzPtODOe1YDXPUDlDNoaUInR6E13-mBtNsJ586NmHnn1k_tkudNsM0O7pnYAMvNgBJlnTd9F469Kek4xhydn-YZdG-PXn3sSfmgsqmF6df9fi07lU778R_TnzYuYhS7h2EHWybrLcupjt6ja4f4z8G-AHtWg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>196647546</pqid></control><display><type>article</type><title>Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Arcaini, L. ; Burcheri, S. ; Rossi, A. ; Paulli, M. ; Bruno, R. ; Passamonti, F. ; Brusamolino, E. ; Molteni, A. ; Pulsoni, A. ; Cox, M.C. ; Orsucci, L. ; Fabbri, A. ; Frezzato, M. ; Voso, M.T. ; Zaja, F. ; Montanari, F. ; Merli, M. ; Pascutto, C. ; Morra, E. ; Cortelazzo, S. ; Lazzarino, M.</creator><creatorcontrib>Arcaini, L. ; Burcheri, S. ; Rossi, A. ; Paulli, M. ; Bruno, R. ; Passamonti, F. ; Brusamolino, E. ; Molteni, A. ; Pulsoni, A. ; Cox, M.C. ; Orsucci, L. ; Fabbri, A. ; Frezzato, M. ; Voso, M.T. ; Zaja, F. ; Montanari, F. ; Merli, M. ; Pascutto, C. ; Morra, E. ; Cortelazzo, S. ; Lazzarino, M.</creatorcontrib><description>Background: Hepatitis C virus (HCV) infection is frequently associated with B-cell non-Hodgkin's lymphomas. We investigated the prevalence of HCV infection in nongastric marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT) in order to define the relationship between the viral infection and the presenting features, treatment, and outcome.
Methods: We retrospectively studied 172 patients with a histological diagnosis of marginal zone B-cell lymphoma of MALT, except for stomach, and with available HCV serology, among a series of 208 patients.
Results: HCV infection was documented in 60 patients (35%). Most HCV-positive patients (97%) showed a single MALT organ involvement. HCV-positive patients showed a more frequent involvement of skin (35%), salivary glands (25%), and orbit (15%). The majority of stage IV HCV-positive patients (71%) had a single MALT site with bone marrow involvement. The overall response rate was similar in HCV-positive (93%) and HCV-negative patients (87%). Overall survival (OS) and event-free survival (EFS) did not differ according to HCV infection. In multivariate analysis, advanced disease (stage III–IV) was associated with a poorer OS (P = 0.0001), irrespective of HCV serostatus.
Conclusions: This study shows that nongastric marginal zone lymphomas are characterized by a high prevalence of HCV infection. Patients with involvement of a single MALT site have the highest prevalence of HCV. HCV-positive nongastric lymphomas of MALT show an indolent course similar to HCV-negative patients and seem an ideal target for exploiting the antilymphoma activity of antiviral treatments.</description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdl388</identifier><identifier>PMID: 17071937</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Antibodies, Viral - analysis ; Antineoplastic agents ; Biological and medical sciences ; Biomarkers - analysis ; Female ; Gastric Mucosa - virology ; Hematologic and hematopoietic diseases ; Hepacivirus - isolation & purification ; Hepatitis C - pathology ; Hepatitis C - virology ; Hepatitis C virus ; Human viral diseases ; Humans ; infectious agents ; Infectious diseases ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Lymphoma, B-Cell, Marginal Zone - pathology ; Lymphoma, B-Cell, Marginal Zone - virology ; Male ; MALT lymphoma ; marginal zone ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Prevalence ; Retrospective Studies ; Survival Rate ; Viral diseases ; Viral hepatitis</subject><ispartof>Annals of oncology, 2007-02, Vol.18 (2), p.346-350</ispartof><rights>2007 European Society for Medical Oncology</rights><rights>2007 INIST-CNRS</rights><rights>Copyright Springer Science & Business Media Feb 2007</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c570t-892d761b71e5528a03765b319a5f8b0ef898744254563e776db8cd72258dea293</citedby><cites>FETCH-LOGICAL-c570t-892d761b71e5528a03765b319a5f8b0ef898744254563e776db8cd72258dea293</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18550865$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17071937$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Arcaini, L.</creatorcontrib><creatorcontrib>Burcheri, S.</creatorcontrib><creatorcontrib>Rossi, A.</creatorcontrib><creatorcontrib>Paulli, M.</creatorcontrib><creatorcontrib>Bruno, R.</creatorcontrib><creatorcontrib>Passamonti, F.</creatorcontrib><creatorcontrib>Brusamolino, E.</creatorcontrib><creatorcontrib>Molteni, A.</creatorcontrib><creatorcontrib>Pulsoni, A.</creatorcontrib><creatorcontrib>Cox, M.C.</creatorcontrib><creatorcontrib>Orsucci, L.</creatorcontrib><creatorcontrib>Fabbri, A.</creatorcontrib><creatorcontrib>Frezzato, M.</creatorcontrib><creatorcontrib>Voso, M.T.</creatorcontrib><creatorcontrib>Zaja, F.</creatorcontrib><creatorcontrib>Montanari, F.</creatorcontrib><creatorcontrib>Merli, M.</creatorcontrib><creatorcontrib>Pascutto, C.</creatorcontrib><creatorcontrib>Morra, E.</creatorcontrib><creatorcontrib>Cortelazzo, S.</creatorcontrib><creatorcontrib>Lazzarino, M.</creatorcontrib><title>Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><description>Background: Hepatitis C virus (HCV) infection is frequently associated with B-cell non-Hodgkin's lymphomas. We investigated the prevalence of HCV infection in nongastric marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT) in order to define the relationship between the viral infection and the presenting features, treatment, and outcome.
Methods: We retrospectively studied 172 patients with a histological diagnosis of marginal zone B-cell lymphoma of MALT, except for stomach, and with available HCV serology, among a series of 208 patients.
Results: HCV infection was documented in 60 patients (35%). Most HCV-positive patients (97%) showed a single MALT organ involvement. HCV-positive patients showed a more frequent involvement of skin (35%), salivary glands (25%), and orbit (15%). The majority of stage IV HCV-positive patients (71%) had a single MALT site with bone marrow involvement. The overall response rate was similar in HCV-positive (93%) and HCV-negative patients (87%). Overall survival (OS) and event-free survival (EFS) did not differ according to HCV infection. In multivariate analysis, advanced disease (stage III–IV) was associated with a poorer OS (P = 0.0001), irrespective of HCV serostatus.
Conclusions: This study shows that nongastric marginal zone lymphomas are characterized by a high prevalence of HCV infection. Patients with involvement of a single MALT site have the highest prevalence of HCV. HCV-positive nongastric lymphomas of MALT show an indolent course similar to HCV-negative patients and seem an ideal target for exploiting the antilymphoma activity of antiviral treatments.</description><subject>Antibodies, Viral - analysis</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - analysis</subject><subject>Female</subject><subject>Gastric Mucosa - virology</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hepacivirus - isolation & purification</subject><subject>Hepatitis C - pathology</subject><subject>Hepatitis C - virology</subject><subject>Hepatitis C virus</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>infectious agents</subject><subject>Infectious diseases</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Lymphoma, B-Cell, Marginal Zone - pathology</subject><subject>Lymphoma, B-Cell, Marginal Zone - virology</subject><subject>Male</subject><subject>MALT lymphoma</subject><subject>marginal zone</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Prevalence</subject><subject>Retrospective Studies</subject><subject>Survival Rate</subject><subject>Viral diseases</subject><subject>Viral hepatitis</subject><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1v1DAQhi0EokvhyBVFSHALteP461hWhUUsKqACFRfLcSbFJbG3drai_fU4zYqVkBAnj-RnXs_4Qegpwa8IVvTIeB-8PRrankp5Dy0I46qUuCb30QKripaC0foAPUrpEmPMVaUeogMisCCKigU6_Rjh2vTgLRShK1bLr4XzHdjRBZ-rIodfmDRGZ4vBxAvnTV_cBg_F69JC3xf9zbD5EQYzNX84Xp89Rg860yd4sjsP0Zc3J2fLVbk-fftuebwuLRN4LKWqWsFJIwgwVkmDqeCsoUQZ1skGQyeVFHVdsZpxCkLwtpG2FVXFZAumUvQQvZxzNzFcbSGNenBpmsh4CNukeQ5gWP0fJIoJyu8Sn_8FXoZtzPtODOe1YDXPUDlDNoaUInR6E13-mBtNsJ586NmHnn1k_tkudNsM0O7pnYAMvNgBJlnTd9F469Kek4xhydn-YZdG-PXn3sSfmgsqmF6df9fi07lU778R_TnzYuYhS7h2EHWybrLcupjt6ja4f4z8G-AHtWg</recordid><startdate>20070201</startdate><enddate>20070201</enddate><creator>Arcaini, L.</creator><creator>Burcheri, S.</creator><creator>Rossi, A.</creator><creator>Paulli, M.</creator><creator>Bruno, R.</creator><creator>Passamonti, F.</creator><creator>Brusamolino, E.</creator><creator>Molteni, A.</creator><creator>Pulsoni, A.</creator><creator>Cox, M.C.</creator><creator>Orsucci, L.</creator><creator>Fabbri, A.</creator><creator>Frezzato, M.</creator><creator>Voso, M.T.</creator><creator>Zaja, F.</creator><creator>Montanari, F.</creator><creator>Merli, M.</creator><creator>Pascutto, C.</creator><creator>Morra, E.</creator><creator>Cortelazzo, S.</creator><creator>Lazzarino, M.</creator><general>Elsevier Ltd</general><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>6I.</scope><scope>AAFTH</scope><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>7U9</scope><scope>7X8</scope></search><sort><creationdate>20070201</creationdate><title>Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT</title><author>Arcaini, L. ; Burcheri, S. ; Rossi, A. ; Paulli, M. ; Bruno, R. ; Passamonti, F. ; Brusamolino, E. ; Molteni, A. ; Pulsoni, A. ; Cox, M.C. ; Orsucci, L. ; Fabbri, A. ; Frezzato, M. ; Voso, M.T. ; Zaja, F. ; Montanari, F. ; Merli, M. ; Pascutto, C. ; Morra, E. ; Cortelazzo, S. ; Lazzarino, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c570t-892d761b71e5528a03765b319a5f8b0ef898744254563e776db8cd72258dea293</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Antibodies, Viral - analysis</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - analysis</topic><topic>Female</topic><topic>Gastric Mucosa - virology</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hepacivirus - isolation & purification</topic><topic>Hepatitis C - pathology</topic><topic>Hepatitis C - virology</topic><topic>Hepatitis C virus</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>infectious agents</topic><topic>Infectious diseases</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Lymphoma, B-Cell, Marginal Zone - pathology</topic><topic>Lymphoma, B-Cell, Marginal Zone - virology</topic><topic>Male</topic><topic>MALT lymphoma</topic><topic>marginal zone</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Prevalence</topic><topic>Retrospective Studies</topic><topic>Survival Rate</topic><topic>Viral diseases</topic><topic>Viral hepatitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Arcaini, L.</creatorcontrib><creatorcontrib>Burcheri, S.</creatorcontrib><creatorcontrib>Rossi, A.</creatorcontrib><creatorcontrib>Paulli, M.</creatorcontrib><creatorcontrib>Bruno, R.</creatorcontrib><creatorcontrib>Passamonti, F.</creatorcontrib><creatorcontrib>Brusamolino, E.</creatorcontrib><creatorcontrib>Molteni, A.</creatorcontrib><creatorcontrib>Pulsoni, A.</creatorcontrib><creatorcontrib>Cox, M.C.</creatorcontrib><creatorcontrib>Orsucci, L.</creatorcontrib><creatorcontrib>Fabbri, A.</creatorcontrib><creatorcontrib>Frezzato, M.</creatorcontrib><creatorcontrib>Voso, M.T.</creatorcontrib><creatorcontrib>Zaja, F.</creatorcontrib><creatorcontrib>Montanari, F.</creatorcontrib><creatorcontrib>Merli, M.</creatorcontrib><creatorcontrib>Pascutto, C.</creatorcontrib><creatorcontrib>Morra, E.</creatorcontrib><creatorcontrib>Cortelazzo, S.</creatorcontrib><creatorcontrib>Lazzarino, M.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Virology and AIDS Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arcaini, L.</au><au>Burcheri, S.</au><au>Rossi, A.</au><au>Paulli, M.</au><au>Bruno, R.</au><au>Passamonti, F.</au><au>Brusamolino, E.</au><au>Molteni, A.</au><au>Pulsoni, A.</au><au>Cox, M.C.</au><au>Orsucci, L.</au><au>Fabbri, A.</au><au>Frezzato, M.</au><au>Voso, M.T.</au><au>Zaja, F.</au><au>Montanari, F.</au><au>Merli, M.</au><au>Pascutto, C.</au><au>Morra, E.</au><au>Cortelazzo, S.</au><au>Lazzarino, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2007-02-01</date><risdate>2007</risdate><volume>18</volume><issue>2</issue><spage>346</spage><epage>350</epage><pages>346-350</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract>Background: Hepatitis C virus (HCV) infection is frequently associated with B-cell non-Hodgkin's lymphomas. We investigated the prevalence of HCV infection in nongastric marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT) in order to define the relationship between the viral infection and the presenting features, treatment, and outcome.
Methods: We retrospectively studied 172 patients with a histological diagnosis of marginal zone B-cell lymphoma of MALT, except for stomach, and with available HCV serology, among a series of 208 patients.
Results: HCV infection was documented in 60 patients (35%). Most HCV-positive patients (97%) showed a single MALT organ involvement. HCV-positive patients showed a more frequent involvement of skin (35%), salivary glands (25%), and orbit (15%). The majority of stage IV HCV-positive patients (71%) had a single MALT site with bone marrow involvement. The overall response rate was similar in HCV-positive (93%) and HCV-negative patients (87%). Overall survival (OS) and event-free survival (EFS) did not differ according to HCV infection. In multivariate analysis, advanced disease (stage III–IV) was associated with a poorer OS (P = 0.0001), irrespective of HCV serostatus.
Conclusions: This study shows that nongastric marginal zone lymphomas are characterized by a high prevalence of HCV infection. Patients with involvement of a single MALT site have the highest prevalence of HCV. HCV-positive nongastric lymphomas of MALT show an indolent course similar to HCV-negative patients and seem an ideal target for exploiting the antilymphoma activity of antiviral treatments.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>17071937</pmid><doi>10.1093/annonc/mdl388</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2007-02, Vol.18 (2), p.346-350 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68985099 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Antibodies, Viral - analysis Antineoplastic agents Biological and medical sciences Biomarkers - analysis Female Gastric Mucosa - virology Hematologic and hematopoietic diseases Hepacivirus - isolation & purification Hepatitis C - pathology Hepatitis C - virology Hepatitis C virus Human viral diseases Humans infectious agents Infectious diseases Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Lymphoma, B-Cell, Marginal Zone - pathology Lymphoma, B-Cell, Marginal Zone - virology Male MALT lymphoma marginal zone Medical sciences Middle Aged Pharmacology. Drug treatments Prevalence Retrospective Studies Survival Rate Viral diseases Viral hepatitis |
| title | Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T04%3A43%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevalence%20of%20HCV%20infection%20in%20nongastric%20marginal%20zone%20B-cell%20lymphoma%20of%20MALT&rft.jtitle=Annals%20of%20oncology&rft.au=Arcaini,%20L.&rft.date=2007-02-01&rft.volume=18&rft.issue=2&rft.spage=346&rft.epage=350&rft.pages=346-350&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdl388&rft_dat=%3Cproquest_cross%3E1212972471%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=196647546&rft_id=info:pmid/17071937&rft_els_id=S0923753419376094&rfr_iscdi=true |